老虎证券

BUZZ-Capricor rises on FDA's priority review for Duchenne muscular dystrophy-related cell therapy

Reuters
03-04
BUZZ-Capricor rises on FDA's priority review for Duchenne muscular dystrophy-related cell therapy

** Shares of Capricor Therapeutics CAPR.O rise ~12% to $15.30 premarket

** Co says the U.S. FDA has granted Priority Review to its drug to treat a heart condition associated with Duchenne muscular dystrophy (DMD)

** DMD cardiomyopathy is a heart muscle disease that can develop in individuals with the genetic condition causing progressive muscle weakness

** FDA is set to decide on the cell therapy, deramiocel, by August 31

** 'Priority review' status reduces the review timeline to six months from the time of filing, compared to a standard review timeline of 10 months

** Up to last close, stock nearly tripled in the past 12 months

(Reporting by Mariam Sunny in Bengaluru)

((Mariam.ESunny@thomsonreuters.com;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10